The compendial microcrystalline cellulose grades PH101, PH102, and PH200 are excipients, not active pharmaceutical ingredients; when procurement documents include “API” in the material name, that term is not a process claim for these grades. This application section addresses the established downstream processes for oral solid and oral granular pharmaceutical manufacturing. The term “injection” is treated as a process boundary rather than a direct application: the median particle sizes of 50 μm, 100 μm, and 200 μm, respectively, place these grades outside the particulate-matter thresholds of USP <788> Method 1 for small-volume injectables, and published data for sterile suspension manufacturing with these specific PH grades is limited. The six scenarios that follow are therefore confined to tablet, capsule, granule, and oral powder processes where compendial and production-scale use is established.

Bulk density values are measured by USP <616> Method I; particle size values are laser-diffraction medians and should be confirmed against the supplier certificate of analysis for each production batch.

Does PH200 Reduce Tablet Weight Variation at High Press Speed Compared with PH102?

In high-speed direct compression of immediate-release tablets, the selection between PH102 and PH200 is a quantified trade-off between compactibility and weight variation, not a simple substitution. PH200 has a median particle size of 200 μm and a bulk density of 0.30–0.36 g/cm³, which allows force-feeder-assisted rotary tablet presses to run at 60–80 rpm with less hopper ratholing than PH102, whose median particle size is 100 μm and whose bulk density is 0.28–0.33 g/cm³. This difference matters when the active substance is present below 5% w/w and segregation is the controlling risk. Batch-to-batch variance in the D10 and D90 of PH200 requires review before scale-up; a D90 exceeding 250 μm can increase segregation in low-dose blends and raise content uniformity failures under USP <905>. The compendial boundary for both grades is the USP-NF Microcrystalline Cellulose monograph and Ph. Eur. 0316, with elemental impurity levels assessed under ICH Q3D. Formulation addition ratios for direct compression extend from 20% w/w to 90% w/w; typical files submitted to regulatory authorities cluster at 50–70% w/w for high-dose actives and 80–90% w/w for low-dose actives where microcrystalline cellulose is the main filler-binder.

On a 45-station rotary press with a force feeder, weight variation is typically controlled below 2.0% RSD with PH200 at press speeds of 60–80 rpm; PH102 can achieve equivalent uniformity only when feeder paddle speed and baffle height are re-validated after each scale-up. The failure mode for PH200 is not flow but compactibility: if the main compression force remains set at 5–8 kN as used for PH102, the larger particle surface area produces insufficient plastic deformation and friability can approach the 1.0% w/w limit of USP <1216>, particularly at 20% w/w loading. Lubrication with magnesium stearate at 0.5–1.0% w/w must be limited to 2–5 min in a bin blender; extended lubrication forms a hydrophobic film over the microcrystalline cellulose surface and reduces tablet tensile strength by 20–30%, as measured by USP <1217>. Pre-drying at 60°C for 2–4 h is required when ambient relative humidity exceeds 60%, because microcrystalline cellulose moisture above 5% w/w changes flow and increases punch sticking. Terminal product types include immediate-release tablets, high-dose generic tablets, and direct-compressed chewable tablets where wet granulation is rejected to avoid residual moisture.

The choice between PH101 and PH102 in hard-shell capsule filling is determined by plug formation and powder flow, and the two grades are not interchangeable without adjusting machine settings. PH101 at 20–40% w/w is used in tamping-pin machines because its 50 μm median particle size and large specific surface area produce a cohesive plug with low elastic rebound after the tamping pins retract; PH102 at 30–70% w/w is preferred for dosator machines and for formulations where hopper flow stops at low fill weights. The formulation addition range of 10–90% w/w is supported by compendial and IIG data, but production-scale blends above 70% w/w microcrystalline cellulose often require a flow aid such as colloidal silicon dioxide at 0.5–1.0% w/w. Lubrication is performed with 0.5–1.0% w/w magnesium stearate or 0.5% w/w sodium stearyl fumarate for 3–5 min; lubricant levels above 2.0% w/w delay disintegration when tested under USP <701> or USP <2040>. Encapsulation is run on intermittent or continuous capsule fillers at 30,000–80,000 capsules/h, with plug weight RSD held below 4.0% and relative humidity below 60% to prevent moisture uptake in the dosing bores. Compliance for the finished product includes USP <905> for content uniformity and 21 CFR 211.110 for in-process weight control. Terminal product types include hard gelatin capsules, HPMC capsules, and immediate-release capsules where direct filling replaces the traditional wet granulation route.

Wet Granulation Endpoint Control with PH101 in High-Shear Mixers

Wet granulated formulations add PH101 at 5–25% w/w because the small 50 μm particle size and wicking capacity provide granule nucleation and binder distribution in high-shear equipment. The dry blend is charged to a 65 L or 150 L high-shear granulator and premixed at impeller speed 50–100 rpm and chopper speed 150–300 rpm for 2–3 min. Purified water or a binder solution is sprayed at 0.5–1.0 L/min until the impeller torque or load cell power demand reaches the validated endpoint corresponding to a granule moisture content of 20–30% w/w; endpoint control by power consumption rather than fixed time is the production-scale method to avoid batch-to-batch variation in granule porosity. Over-wetting above 30% w/w leads to oversized granules after wet milling and prolongs fluid-bed drying, while under-wetting below 18% w/w leaves fines that segregate in the tablet press feeder.

The wet mass is passed through a conical mill or oscillating mill with screen aperture 4.0 mm, dried in a fluid-bed dryer at inlet air temperature 60–70°C, and dried to a final loss-on-drying of 2–4% w/w. Product temperature is maintained below 40°C to preserve heat-labile actives and to prevent case-hardening of granules. Compliance for the wet granulation process is governed by ICH Q3D for elemental impurities, USP <467> for residual solvents, and USP <61>/<62> for microbiological limits because process water is introduced. Terminal product types include film-coated tablets, immediate-release tablets, and granules that are filled into hard capsules or sachets after dry milling to a particle size below 1.0 mm.

Dry granulation and roller compaction are deployed when a moisture-sensitive active prohibits wet granulation or when continuous processing is required. PH102 is added at 10–50% w/w, with 20–40% w/w as the typical pre-compaction range, because its particle size and plastic deformation behaviour allow ribbon formation without generating excessive fines. The blend is passed through a roller compactor with roll force adjusted to produce ribbons with solid fraction 0.50–0.65 and thickness 1.0–3.0 mm; the ribbons are milled through an oscillating mill with 0.8 mm or 1.0 mm screen and screened to remove both undersized and oversized fractions. The undersized fraction is recycled at 20–35% w/w to stabilise granule density, but recycle ratios above 40% w/w introduce work-hardened particles that increase capping at main compression forces above 15 kN. The process is governed by Ph. Eur. 0316 for the excipient, ICH Q3C for residual solvents in any pre-blend, and USP <905> for content uniformity of the final tablets. Terminal product types include immediate-release tablets for moisture-sensitive actives, dose-titration tablets produced without water, and roller-compacted granules intended for further blending or filling.

When an Orodispersible Tablet Requires Disintegration Below 30 Seconds

The defining constraint in orodispersible tablet design is the disintegration threshold below 30 s measured under USP <701> or Ph. Eur. 2.9.1 at 37±2°C. PH101 or PH102 is incorporated at 10–30% w/w to provide a porous tablet matrix, but the process window is narrow. Pilot and production-scale compression on a rotary tablet press at 20–40 rpm requires main compression force limited to 3–8 kN; this yields crushing strength of 20–50 N and friability below 1.0% w/w. If the force exceeds 8 kN with PH102, disintegration can exceed 30 s because pore closure reduces water entry. PH101 produces smaller pores and faster wicking but may require a superdisintegrant such as crospovidone or croscarmellose sodium at 2–5% w/w to achieve the same disintegration threshold without excessive hardness loss. Compliance for the finished orodispersible tablet includes ICH Q3D for elemental impurities, the USP-NF Microcrystalline Cellulose monograph, and USP <905> for content uniformity in low-dose units. Terminal product types include orodispersible tablets, rapid-dissolving tablets, and pediatric dispersible tablets compressed from a dry blend without granulation.

PH101 in Sachet and Dry Syrup Granules Is Governed by Fines and Heat-Seal Integrity

For oral powder and dry syrup granules filled into sachets, PH101 and PH102 are added at 10–50% w/w to improve content uniformity and reduce hygroscopic caking during storage. PH101 increases the mass fraction below 45 μm, which can deposit on the forming collar and heat-seal jaws of vertical form-fill-seal machines at line speeds above 40 sachets/min; PH102 lowers the sub-45 μm fraction and is therefore preferred for continuous sealing when the formulation contains less than 2% w/w glidant. The granules or powders are blended in a low-shear bin blender for 10–20 min and filled into low water-vapour-permeability laminate sachets at ambient relative humidity below 60% to prevent moisture uptake that would reduce flowability and compromise heat-seal integrity. Compliance for the filled sachets follows USP <905> for content uniformity and Ph. Eur. 2.9.5 for uniformity of mass of single-dose preparations, and the excipient itself must conform to USP-NF Microcrystalline Cellulose and Ph. Eur. 0316. Terminal product types include dry syrups for reconstitution, oral granule sachets, and multi-dose powder formulations for pediatric or geriatric administration.